Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)

Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2003, Pages 49-63

  Wissner, Allan ^a   Overbeek, Elsebe ^a   Reich, Marvin F ^a   Floyd, M Brawner ^a   Johnson, Bernard D ^a   Mamuya, Nellie ^a   Rosfjord, Edward C ^a   Discafani, Carolyn ^a   Davis, Rachel ^a   Shi, Xiaoqing ^a   Rabindran, Sridhar K ^a   Gruber, Brian C ^a   Ye, Fei ^a   Hallett, William A ^a   Nilakantan, Ramaswamy ^a   Shen, Ru ^a   Wang, Yu Fen ^a   Greenberger, Lee M ^a   Tsou, Hwei Ru ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID ANHYDRIDE; AMIDE; CHLORIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; QUINOLONE DERIVATIVE; RECEPTOR SUBTYPE;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CATALYSIS; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MICHAEL ADDITION; MOLECULAR MODEL; MOUSE; NONHUMAN; SOLUBILITY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; MICE; MODELS, MOLECULAR; ORGANIC CHEMICALS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037413550     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020241c     Document Type: Article

References (40)

1. Plowman, G. D.; Ullrich, A.; Shawver, L. K. Receptor tyrosine kinases as targets for drug intervention. Drug News Perspect. 1994, 7, 334-337.
2. Salomon, D. S.; Brandt, R.; Ciadiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Haematol. 1995, 19, 183-232.
3. (b) Gullick, W. J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 1991, 47, 87-98.
4. (c) Woodburn, J. R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999, 82, 241-250.
5. (a) Ekstrand, A. J.; Sugawa, N.; James, C. D.; Collins, V. P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4309-4313.
6. (b) Wikstrand, C. J.; McLendon, R. E.; Friedman, A.; Bigner, D. D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997, 57, 4130-4140.
7. Olapade-Olaopa, E. O.; Moscatello, D. K.; MacKay, E. H.; Horsburgh, T.; Sandhu, D. P. S.; Terry, T. R.; Wong, A. J.; Habib, F. K. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer 2000, 82, 186-194.
8. Moscatello, D. K.; Holgado-Mudruga, M.; Godwin, A. K.; Ramirez, G.; Gunn, G.; Zoltick, P. W.; Biegel, J. A.; Hayes, R. L.; Wong, A. J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995, 55, 5536-5539.
9. Garcia de Palazzo, I. E.; Adams, G. P.; Sundareshan, P.; Wong A. J.; Testa, J. R.; Bigner, D. D.; Weiner L. M. Expression of mutated epidermal growth factor receptor by nonsmall cell lung carcinomas. Cancer Res. 1993, 53, 3217-3220.
10. Ekstrand, A. J.; Longo, N.; Hamid, M. L.; Olson, J. J.; Liu, L.; Collins, V. P.; James, C. D. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994, 9, 2313-2320.
11. Cohen, D. W.; Simak, R.; Rair, W. R.; Melamed, J.; Scher, H. I.; Cordon-Cardo, C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J. Urol. 1994, 152, 2120-2124.
12. Grandis, J. R.; Melhem, M. F.; Gooding, W. E.; Day, R.; Holst, V. A.; Wagener, M. M.; Drenning, S. D.; Tweardy, D. J. Levels of TGFα and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 1998, 90, 824-832.
13. Morishigie, K. I.; Kurachi, H.; Ameniya, K.; Fujita, Y.; Yamamoto, T.; Mikaye, A.; Tanizawa, O. Evidence for the involvement of TGFα and EGFR autocrine mechanism in primary ovarian cancers in vitro. Cancer Res. 1991, 51, 5322-5328.
14. Rusch, V.; Klimstra, D.; Venkatraman, E.; Pisters, P. W. T.; Langenfeld, J.; Dmitrovsky, E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable nonsmall cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 1997, 3, 515-522.
15. Thogersen, V. B.; Jorgensen, P. E.; Sorensen, B. S.; Bross, P., Orntoft, T.; Wolf, H.; Nexo, E. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer. Scand. J. Clin. Lab Invest. 1999, 59, 267-277.
16. Sweeney Jr., W. E.; Chen, Y.; Nakanishi, K.; Frost, P.; Avner, E. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000, 57, 33-40.
17. (a) Elder, J. T.; Fisher, G. J.; Lindquist, P. B.; Bennett, G. J.; Pittelkow, M. R.; Coffey, R. J.; Ellingsworth, L.; Derynck, R.; Voorhees, J. J. Overexpression of transforming growth factor-α in psoriatic epidermis. Science 1989, 243, 811-814.
18. (b) Cook, P. W.; Peipkorn, M.; Clegg, C. H.; Plowman, G. D.; DeMay, J. M.; Brown, J. R.; Pittelkow, M. R. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J. Clin. Invest. 1997, 100, 2286-2294.
19. Davies, D. E.; Polosa, R.; Puddicombe, S. M.; Richter, A.; Holgate, S. T. The epidermal growth factor receptor and its ligand family: Their potential role in repair and remodelling in asthma. Allergy 1999, 54, 771-783.
20. (a) Yamamoto, T.; Ikawa, S.; Akiyama, T.; Semba, K.; Nomura, N.; Miyajima, N.; Saito, T.; Toyoshima, K. Similarity of protein encoded by the human c-erb·B gene to the epidermal growth factor receptor. Nature 1986, 319, 230-234.
21. (b) Coussens, L.; Yang-Feng, T. L.; Liao, Y.-C.; Chen, E.; Gray, A.; McGrath, J.; Seeburg, P. H.; Libermann, T. A.; Schlessinger, J.; Francke, U.; Levinson, A.; Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230, 1132-1139.
22. Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyd, M. B. Jr., Greenberger, L. M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H.-R.; Upeslacis, E.; Wang, Y.-F.; Wu, B.; Ye, F.; Zhang, N. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor (EGF-R) kinase and their bioisosteric relationship to the 4-Anilino-6,7-dialkoxyquinazoline inhibitors. J. Med. Chem. 43, 2000, 3244-3256.
23. (a) Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
24. (b) Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharm. 1994, 48, 659-666.
25. (a) Wang, Y. D.; Miller, K.; Boschelli, D. H.; Ye, F.; Wu, B.; Floyd, M. B.; Powell, D. W.; Wissner, A.; Weber, J. M.; Boschelli, F. Inhibitors of Src tyrosine kinase: The preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett. 2000, 10, 2477-2480.
26. (b) Boschelli, D. H.; Wang, Y. D.; Ye, F.; Wu, B.; Zhang, N.; Dutia, M.; Powell, D. W.; Wissner, A.; Arndt, K.; Weber, J. M.; Boschelli, F. Synthesis and Src kinase inhibitory activity of a series of 4-Phenylamino-3-quinolinecarbonitriles. J. Med. Chem. 2001, 44, 822-833.
27. (c) Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.; Johnson, S. L.; Wu, B.; Miller, K.; Powell, D. W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-Phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J. Med. Chem. 2001, 44, 3965-3977.
28. (a) Zhang, N.; Wu, B.; Powell, D.; Wissner, A.; Floyd, M. B.; Kovacs, E. D.; Toral-Barza, L.; Kohler, C. Synthesis and structure-activity relationships of 3-Cyano-4-(phenoxyanilino)-quinolines as MEK (MAPKK) inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2825-2828.
29. (b) Zhang, N.; Wu, B.; Eudy, N.; Wang, Y.; Ye, F.; Powell, D.; Wissner, A.; Feldberg, L. R.; Kim, S. C.; Mallon, R.; Kovacs, E. D.; Toral-Barza, L.; Kohler, C. A. MEK(MAPKK) inhibitors. Part 2: Structure-activity relationships of 4-Anilino-3-cyano-6,7-dialkoxyquinolines. Bioorg. Med. Chem. Lett. 2001, 11, 1407-1410.
30. (a) Wissner, A.; Johnson, B. D.; Floyd, M. B.; Kitchen, D. B. 4-Aminoquinazolines as EGFR inhibitors. U.S. Patent 5760041, 1998.
31. (b) Discafani, C. M.; Carroll, M. L.; Floyd, M. B. Jr.; Hollander, I. J.; Husain, Z.; Johnson, B. D.; Kitchen, D.; May, M. K.; Malo, M. S.; Minnick, A. A. Jr.; Nilakantan, R.; Shen, R.; Wang, Y.-F.; Wissner, A.; Greenberger, L. M. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vitro activity by N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387785). Biochem. Pharmacol. 1999, 57, 917-925.
32. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Gries, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12022-12027.
33. Tsou, H.-R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y.-F.; Wissner, A. 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 44, 2001, 2719-2734.
34. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Wissner, A.; Kinzler, K. W.; Vogelstein, B; Frost, P.; Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6, 2000, 1024-1028.
35. Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Showalter, H. D. H.; Wincent, P. W.; Elliott, W. L.; Denny, W. A. Tyrosine Kinase Inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)-pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 2000, 43, 1380-1397.
36. (a) Bredereck, H.; Effenberger, F.; Borsch, H.; Rehn, H. Synthesen in der heterocyclischen reihe V. Umsetzungen von vinylogen carbonsäureamiden zu heterocyclen. Chem Ber. 1965, 98, 1081-1086.
37. (b) Egri, J.; Halmos, J.; Rakoczi, J. Synthesis of substituted 4-Hydroxyquinoline-3-carboxylic esters, IV. Acta Chim (Budapest) 1973, 78, 217-225.
38. Bellassoued, M.; Habbachi, F.; Gaudemar, M. Silicon in organic synthesis: An improved 4-bromination of 2-alkenoic acids. Synthesis 1983, 745-746.
39. Krawczyk, H. The mannich reaction of malonic acid. An efficient route to some α-functionalized acrylates. Synth. Commun. 1995, 25, 641-650.
40. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-Anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-Anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43, 133-138.